Blood Clots

Tretten approved for genetic clotting disorder

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

Dec 23, 2013
popularity not rated yet | comments 0

Results of the TATORT-NSTEMI trial presented

According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard ...

Nov 01, 2013
popularity not rated yet | comments 0

Latest Spotlight News

Building 'smart' cell-based therapies

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other ...